RealFeedApp Oyster Therapeutics raised $60 million
Oyster Therapeutics, a London-based startup, secured $60 million in an extended Series A round to fund the development of protein degraders designed to eliminate tau protein aggregates in Alzheimer's patients.
- Field
- industry news
- What they did
- London biotech startup Oyster Therapeutics raised $60 million in a Series A funding extension to develop drugs that break up tau protein clumps.
- Why it matters
- Current treatments targeting amyloid proteins only modestly improve cognition and do not stop or reverse Alzheimer's disease, leaving room for better complementary medicines.
#tau protein#alzheimer's#protein degraders#oyster therapeutics#series a
